Search

Precision medicine approaches often rely on complex and integrative analyses of multiple biomarkers from "omics" data to generate insights that can help with either diagnostic, prognostic, or therapeutical decisions. Such insights are often made using machine learning (ML) models that perform sample classification for a particular phenotype (yes/no). Building such models is a challenge and time-consuming, requiring advanced coding skills and mathematical modelling expertise. Artificial intelligence (AI) is a methodological solution that has the potential to facilitate, optimize, and scale model development. In this work, we developed an AI-based, user-friendly, and code-free platform that fully automated the development of predictive models from quantitative "omics" data. Here, we show the application of this tool with the development of cancer survival prognostics models using real-life data from breast, lung, and renal cancer transcriptomes. In comparison to other models, our generated models rendered performances with competitive sensitivities (72–85%), specificities (76–85%), accuracies (75–85%), and Receiver Operating Characteristic curves with superior Areas Under the Curve (ROC-AUC of 77–86%). Further, we reported the associated sets of genes (biomarkers) and their expression patterns that were predictive of cancer survival. Moreover, we made our models available as online tools to generate prognostic predictions based on the gene expressions of the biomarkers. In conclusion, we demonstrated that our tool is a robust, user-friendly solution for developing bespoke predictive tools from "omics" data, which facilitate precision medicine applications to the point-of-care. [ABSTRACT FROM AUTHOR]